Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Panagiotis Gklinos"'
Autor:
Panagiotis Gklinos, Ruth Dobson
Publikováno v:
Antibodies, Vol 13, Iss 2, p 43 (2024)
Clinical syndromes associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) are now recognized as a distinct neurological disease entity, and are gaining increasing attention. The pathogenic mechanisms underlying MOG-antibody dise
Externí odkaz:
https://doaj.org/article/984b55a1af1f4c658726aaa8dc80b6f6
Autor:
Panagiotis Gklinos, Ruth Dobson
Publikováno v:
Pharmaceuticals, Vol 16, Iss 5, p 770 (2023)
The use of high-efficacy disease-modifying therapies (DMTs) early in the course of multiple sclerosis (MS) has been shown to improve clinical outcomes and is becoming an increasingly popular treatment strategy. As a result, monoclonal antibodies, inc
Externí odkaz:
https://doaj.org/article/9ab87b97c62645f399d5dd7cfc68dc17
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Background: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab sh
Externí odkaz:
https://doaj.org/article/c8a906f00ecb422b90d6c46d34730f22
Publikováno v:
Pharmaceuticals, Vol 14, Iss 3, p 245 (2021)
Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in
Externí odkaz:
https://doaj.org/article/13395a754b70492990753e03b2475efe
Autor:
Panagiotis Gklinos, Miranta Papadopoulou, Vid Stanulovic, Dimos D. Mitsikostas, Dimitrios Papadopoulos
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 92 (2021)
Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological c
Externí odkaz:
https://doaj.org/article/ed8719d5c6104431b381d8bae361265e
Autor:
Panagiotis Gklinos, Ruth Dobson
Publikováno v:
British Journal of Neuroscience Nursing. 19:S34-S38
Menopause signals a major shift in hormonal levels in women and causes a variety of symptoms that can overlap and/or interact with those related to multiple sclerosis (MS). These symptoms can have considerable impact on the quality of life for many w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::101fc08075bb2d601d65f860dc5b201f
https://doi.org/10.12968/bjnn.2023.19.sup1.s34
https://doi.org/10.12968/bjnn.2023.19.sup1.s34
Autor:
Panagiotis Gklinos
Publikováno v:
SVOA Neurology. 4
Hyperosmolar hyperglycemic state (HHS), a life-threatening complication of diabetes mellitus, may initially manifest with a broad spectrum of neurological symptoms. These include encephalopathy, coma, chorea-hemiballismus and epileptic activity. Foca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409a42f79614d1dcf1c1f6c0c7ceb2f5
https://doi.org/10.58624/svoane.2023.04.084
https://doi.org/10.58624/svoane.2023.04.084
Autor:
Dimitrios Papadopoulos, Panagiotis Gklinos, Giorgos Psarros, Konstantina Drellia, Eumorphia Maria Delicha, Tim Friede, Dimos D. Mitsikostas, Richard S. Nicholas
Publikováno v:
Journal of neurology. 269(6)
Our study aimed to estimate the incidence of neoplasms in clinical trials of DMTs for MS and to test the hypothesis that DMTs increase the risk of neoplasms in the duration of MS randomized controlled trials (RCTs).Data were extracted from 42 RCTs of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0571bbc547dd3cd1b45817dbac239e8f
https://pubmed.ncbi.nlm.nih.gov/35066607
https://pubmed.ncbi.nlm.nih.gov/35066607
Publikováno v:
Multiple sclerosis and related disorders. 36
Background Nocebo phenomena are linked to decreased adherence to treatments in clinical practice as well as difficulty in assessing the adverse effect profile in clinical trials. Objective To estimate the incidence and severity of nocebo responses in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f553b816058c09eee2c3cb187183528c
https://pubmed.ncbi.nlm.nih.gov/31525626
https://pubmed.ncbi.nlm.nih.gov/31525626
Publikováno v:
Pharmaceuticals, Vol 14, Iss 245, p 245 (2021)
Pharmaceuticals
Pharmaceuticals
Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::297a554635fe4fdf2abd2d06ad00f681
https://doi.org/10.3390/ph14030245
https://doi.org/10.3390/ph14030245